

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : A61K 7/32, 7/46</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/01358 (43) International Publication Date: 13 January 2000 (13.01.00)</p>
<p>(21) International Application Number: PCT/GB99/02170 (22) International Filing Date: 6 July 1999 (06.07.99) (30) Priority Data: 9814646.7 7 July 1998 (07.07.98) GB (71) Applicant (for all designated States except US): QUEST INTERNATIONAL B.V. [NL/NL]; Huizerstraatweg 28, NL-1411 GP Naarden (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): BEHAN, John, Martin [GB/GB]; The Forge, The Green, Boughton Aluph, Ashford, Kent TN25 4JB (GB). MINHAS, Tony [GB/GB]; 30 King Edward Avenue, Dartford, Kent DA1 2HZ (GB). (74) Agents: HUMPHRIES, Martyn et al.; ICI Group Intellectual Property, P.O. Box 90, Wilton, Middlesbrough, Cleveland TS90 8JE (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</p>
<p>(54) Title: METHOD OF REDUCING OR PREVENTING MALODOUR</p> <p>(57) Abstract</p> <p>A method for reducing or preventing body malodour by topically applying to human skin perfume components capable of inhibiting the production of odoriferous steroids by microorganisms on the skin. The perfume components are capable of inhibiting bacterial 4-ene reductase and/or 5<math>\alpha</math>-reductase.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### METHOD OF REDUCING OR PREVENTING MALODOUR

This invention relates to perfume components, mixtures thereof and perfume compositions, to personal products and detergent products containing such perfumes, and to the use of such perfumes and products to deliver a deodorant effect.

5 In particular, it relates to perfume components, mixtures thereof, and perfume compositions for inhibiting the production of odoriferous metabolites by topically applying to human skin perfumery components capable of inhibiting the production of odoriferous steroids by micro-organisms present on the skin surface by inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.

10 It is well known that freshly secreted sweat is odourless and that body malodour is the result of a biotransformation of the sweat by micro-organisms living on the surface of the skin to produce volatile odoriferous compounds.

There are three types of personal product routinely used to combat body malodour: perfumes, antiperspirants and deodorants.

15 Perfumes may simply mask body malodour. However perfume compositions have been disclosed which exhibit a deodorant action. EP-B-3172, EP-A-5618, US-A-43044679, US-A-4322308, US-A-4278658, US-A-4134838, US-A-4288341 and US-A-4289641 all describe perfume compositions which exhibit a deodorant action when applied to human skin or when included in a laundry product used to launder textiles.

20 Antiperspirants work by blocking the sweat glands thereby reducing perspiration.

Antimicrobial agents used in deodorants are designed to reduce the population of micro-organisms living on the surface of the skin. Typical agents of this nature include ethanol and Triclosan (2',4,4'-trichloro-2-hydroxy-diphenyl ether) which are well known to exert antimicrobial effects. The use of common deodorant actives results in a non-selective  
25 antimicrobial action exerted upon most of the skin's natural microflora. This is an undesirable disadvantage of such deodorant formulations.

Gower et al. (J Steroid Biochem. Molec. Biol., (1994) Vol. 48, No. 4, pp 409-418) discloses the importance of certain bacterial enzymes involved in bacterial steroid metabolism in the production of odoriferous steroids.

30 Chen et al. (Dermatology, (1996) Vol. 193, pp 177-184) describes the importance of mammalian 5 $\alpha$ -reductase in seborrhoea, acne, female hirsutism and androgenic alopecia. It also discusses the potential use of 5 $\alpha$ -reductase inhibitors, in particular finasteride and turosteride in treatment of the above conditions.

Liao et al. (Biochemical and Biophysical Research Communications, (1995) Vol. 214,  
35 No. 3, pp 833-838) describes the selective inhibition of mammalian steroid 5 $\alpha$ -reductase.

Russell and Wilson (Annual Review of Biochemistry, (1994) Vol. 63, pp 25-61) describes the moderate efficacy of polyunsaturated fatty acids in inhibiting the mammalian 5 $\alpha$ -reductase enzymes. In particular it compares the ability of polyunsaturated fatty acids to inhibit these enzymes along with the inability of their mono-unsaturated and saturated  
40 counterparts.

US-A-5643559 (Colgate-Palmolive Company) discloses deodorant active materials

having an effective amount of Zn<sup>2+</sup> ions for inhibiting bacterial exoenzymes responsible for the production of axillary malodour. The bacterial exoenzymes are further characterised as aryl sulphatase or beta-glucuronidase.

DE-4343265 (Henkel) describes deodorant compositions comprising saturated dioic acid (C3-C10) esters. The active inhibits a sweat decomposing esterase and the compositions are said to not disturb the skin's natural microflora.

WO 94/07837 (Unichema) describes certain novel unsaturated dioic acids having between 8 and 22 carbon atoms. The potential use of these acids to treat malodour is also described.

10 Accordingly, the invention provides a cosmetic method for reducing or preventing body malodour by topically applying to human skin a composition comprising an active agent capable of inhibiting the production of odoriferous steroids by micro-organisms on the skin surface, wherein the agent is a perfume component which is capable of inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.

15 The invention also provides the use of a perfume component to inhibit bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.

The invention further provides the use of a perfume composition, comprising at least 30% by weight of one or more perfume components capable of inhibiting bacterial 4-ene reductase and/or 5-reductase, to reduce body malodour.

20 The invention further provides the use of a deodorant product, comprising a perfume component, to reduce body malodour by inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.

The invention further provides a perfume composition comprising at least 30% by weight of one or more of the following perfume components;

25 (Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl-cyclohex-2-en-1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methoxy)-4-propyl-1-benzenol), 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methyl-propanal,  $\alpha$ -ionone,  $\beta$ -ionone, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)-cyclohex-3-ene carbaldehyde, methyl  
30 iso-eugenol, tetrahydrolinalol, coriander, benzyl salicylate, dupical, phenyl ethyl alcohol, 9-decenol, clove leaf oil distilled, citral, vanillin, and a deodorant product comprising such a perfume composition.

The invention still further provides a method of producing a perfume composition  
35 which comprises (i) evaluating perfume components on the ability to inhibit bacterial 4-ene reductase and/or 5-reductase, (ii) selecting perfume components on the ability to inhibit bacterial 4-ene reductase and/or 5 $\alpha$ -reductase, and (iii) mixing together two or more of said selected perfume components, optionally with other perfume components.

The term "perfume component" is used herein to represent a material which is added  
40 to a perfume to contribute to the olfactive properties of the perfume. A perfume component can be acceptably employed to provide odour contributions to the overall hedonic

performance of products. Typically, a perfume component will be generally recognised as possessing odours in its own right, will be relatively volatile and often has a molecular weight within the range 100 to 300. Typical materials which are perfume components are described in "Perfume and Flavour Chemicals", Volumes I and II (Steffan Arctander, 1969). A perfume composition will contain a number of individual perfume components, and optionally a suitable diluent. The concentration of perfume components referred to herein is relative to the total concentration of perfume components present in the composition, ie excludes any diluent.

The cosmetic method according to the invention comprises topically applying to human skin active perfume components capable of inhibiting the production of odoriferous steroids by micro-organisms present on the skin surface. Preferably, the method reduces the production of odoriferous steroids sub-lethally. Preferably, the bacterial production of odoriferous steroids is reduced by at least 50%, more preferably by at least 70%, particularly by at least 80%, and especially by at least 90%, whilst preferably maintaining a cell viability of at least 70%, more preferably of at least 80%, and particularly of at least 90%. The sub-lethal effect of a perfume component preferably occurs at concentrations below its minimum inhibitory concentration, determined as described in Example 1 below.

The perfume components used in the present invention are frequently incorporated into deodorant products which include, but are not limited to, body deodorants and antiperspirants including roll ons, gel products, stick deodorants, antiperspirants, shampoos, soaps, shower gels, talcum powder, hand creams, skin conditioners, sunscreens, sun fan lotions, skin and hair conditioners.

The perfume components may also be usefully employed for deodorant properties by incorporation into other products, for example, in to laundry and household products such as rinse conditioners, household cleaners and detergent cleaners. The perfume components can be incorporated into textiles themselves during their production using techniques known in the art, to provide deodorant protection.

It has been shown that the bacterial production of odoriferous steroids can be reduced or eliminated without significantly disturbing the skin's natural microflora. This is achieved by inhibiting bacterial enzymes responsible for the production of odoriferous steroids, in particular the 16-androstenes.

It has also been shown that many inhibitors of mammalian 5 $\alpha$ -reductase, e.g. finasteride, are incapable of sub-lethally inhibiting the bacterial production of odoriferous steroids.

The odoriferous steroids which are inhibited by the method of the invention include the products or intermediates of bacterial steroid metabolism, in particular the 16 androstenes.

In a preferred method according to the invention, an Odour Reduction Value, measured as described in Example 3, of at least 10%, more preferably at least 30%, and particularly at least 50% is obtained. The active perfume components may be mixed with other perfume components to deliver perfumes or perfume compositions with the desired deodorant and hedonistic properties. To deliver high deodorant effects the active

components preferably comprise 30% or more of the total perfume formulation by weight, more preferably at least 40% and particularly at least 60%. A deodorant product preferably comprises at least 0.05% to 4%, more preferably 0.1% to 2% by weight of the active perfume components. Preferred actives include the following perfume components.

- 5 (Z)-3,4,5,6-pentamethylhept-3-en-2-one (Acetyl di iso amylen)
- Mixtures of diethyl- and dimethyl-cyclohex-2-en-1-one (Azarbre)
- Citronellol
- 2-methyl-3-(4-(1-methylethyl)phenyl)propanal (Cyclamen aldehyde)
- (2-(methyloxy)-4-propyl-1-benzenol) (Dihydroeugenol)
- 10 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde (Empetaal)
- 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde (Empetaal)
- 3-(1,3-benzodioxol-5-yl)-2-methylpropanal (Helional)
- $\alpha$ -ionone,  $\beta$ -ionone and mixtures thereof (Ionone)
- 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde (Lyrall)
- 15 3-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde (Lyrall)
- Methyl iso-eugenol
- Tetrahydrolinalol
- Coriander
- Benzyl Salicylate
- 20 Dupical
- Phenyl Ethyl Alcohol
- 9-Decenol
- Clove Leaf Oil Distilled
- Citral
- 25 Vanillin.

A perfume composition for use in the present invention preferably comprises at least 5, more preferably at least 10, and particularly at least 15 of the above perfume components.

The invention is illustrated by the following examples.

### 30 **EXAMPLE 1**

The minimum inhibitory concentration of perfume components was determined by the following method.

- A fresh culture of the test inoculum (Corynebacteria xerosis NCTC 7243 (National Collection of Type Cultures, Public Health Laboratory Service, Central Public Health
- 35 Laboratory, 61 Colindale Avenue, London)) diluted in sterile 0.1% special peptone solution to give a concentration of approximately  $10^6$  cfu/ml was prepared.

- Test samples were diluted in sterile trptone soya broth (TSB) Each row of the microtitre plate (labelled A - H) was allocated to one sample, i.e. eight samples per plate. Row 8 (H) contained only TSB for use as a bacterial control to indicate level of turbidity in
- 40 the absence of test material. Aseptically 200  $\mu$ l of the initial dilution was transferred to the 1st and 7th well of the appropriate row. All other test wells were filled with 100  $\mu$ l of sterile

TSB using an 8 channel pipette. The contents of all wells in column 1 were mixed by sucking samples up and down pipette tips before 100 µl was transferred to column 2. The same sterile pipette tips can be used to transfer 100 µl of each well in column 7 in to the appropriate well in column 8. Tips were discarded into disinfectant solution. Using fresh  
5 sterile tips the process was repeated by transferring 100 µl from column 2 into column 3 (and 8 into 9). The process was continued until all wells in columns 6 and 12 contained 200 µl. After mixing 100 µl was discarded from wells in these columns to waste.

To all wells 100 µl of pre-diluted test culture was added giving 200 µl final volume in each well.

10 A blank plate was prepared for each set of samples using the above protocol except 100 µl of sterile 0.1% peptone was added instead of bacterial culture.

Plates were sealed using autoclave tape and incubated overnight at 35° C.

The reader was preset to gently agitate the plates to mix the contents before reading absorbance at 540 nm. The control plate for each set of samples was read first. The reader  
15 was then reprogrammed to use the control readings to blank all other plate readings of the set of test materials (i.e. removing turbidity due to perfume and possible colour changes during incubation) thus only printing out absorbances due to turbidity resulting from bacterial growth. Limits were set so that degrees of turbidity were given a rating.

The MIC was taken as the level of sample required to inhibit growth completely  
20 (change in absorbance < 0.2).

#### EXAMPLE 2

The ability of perfume components to inhibit the bacterial 4-ene reductase enzyme was determined in vitro using the conditions given below. The perfume components were tested at a range of concentrations (eg 500 ppm and 1000 ppm) below their predetermined  
25 minimum inhibitory concentration.

The experiments were carried out in sterile glass screw capped vials containing a suspension (1 ml) of an ungrouped coryneform species deposited as NCIMB 13589 (deposited under the Budapest Treaty with National Collections of Industrial and Marine Bacteria Ltd, 23 St Machar Drive, Aberdeen Scotland, UK on 28 June 1999), isolated from  
30 human underarm samples capable of mediating the reduction of the unsaturated double bond at position 4 of an unsaturated steroid molecule. This was prepared from a 24h culture of bacteria grown in growth medium, washed in potassium phosphate buffer (50mM, pH 6.0), and resuspended in biotransformation medium, as described below. Active-emulsion and substrate (androstadienone 50µg/ assay) were added to the bacterial suspension and  
35 experimental samples incubated over 24h at 35°C with agitation (100rpm). Biotransformation of androstadienone to androstenone was measured by capillary GC-MS analysis of the cultures following solvent extraction (Folch et al., J. Biol. Chem. 226: 498-509) with an internal standard, androsterone. Enzyme inactivation of bacterial 4-ene reductase was measured by capillary GC-MS using a Hewlett Packard 5972 MSD GC-MS  
40 fitted with a 30m x 0.32 mm HP-5 fused silica capillary column (0.25 µm film thickness) and helium carrier gas. The injection temperature was 80°C, which was held for 1 min, then

increased to 200°C at 10°C/ min, then to 300°C at 20°C/min, with the final iso time of 10 min. Androstenone was identified from fragmentation patterns and standards, and levels in the biotransformation samples were determined using the internal standard and calibration curves of androstenone.

- 5 Growth media used for the preparation of the bacterial inoculum was composed of 200 ml of tryptone soya broth (20g/l), yeast extract (10g/l), and Tween 80 (2.5g/l). Biotransformation was carried out in the medium published previously (Kawahara, F. S. (1969) Meths. Enzymol. V, 527-532). In addition it is possible to carry out this reaction in medium (TSBT) defined by Gower et al, Journal of Steroid Biochemistry and Molecular
- 10 Biology, Vol. 48, No. 4, pp 409-418. The active emulsion was prepared using potassium phosphate buffer (50mM, pH 6.0), supplemented with Triton X 100 (5g/l).

### EXAMPLE 3

The following are typical formulations of deodorant products which comprise a perfume or perfume component capable of inhibiting the production of odoriferous steroids.

- 15 These formulations are made by methods common in the art.

#### Deodorant Sticks

Ingredient	Content (% by weight)	
	Formulation 1A	Formulation 1B
Ethanol		8.0
Sodium Stearate	7.0	6.0
Propylene glycol	70.0	12.0
Perfume	1.5	2.0
PPG-3 Myristyl ether		28.0
PPG-10 Cetyl ether		10.0
Cyclomethicone		34.0
Silica		
Water	21.5	

#### Aerosols

Ingredient	content % by weight	
	Formulation 2A	Formulation 2B
Ethanol B	up to 100	
Propylene glycol	as required	
Perfume	2.5	1.5



Chlorhydrol microdry		31.8
Silicone Fluid DC344		up to 100
Bentone gel IPP		13.65
Irgasan DP300	0.03	
Dimethyl ether	20.0	
Concentrate		22.0
Water	23.0	

**Roll ons**

Ingredient	Content % by weight	
	Formulation 3A	Formulation 3B
Ethanol	to 100%	60.0
Klucel MF		0.65
Cremphor RM410		0.5
Perfume	0.5	1.0
AZTC*	20.0	
Cyclomethicone	68.0	
Dimethicone	5.0	
Silica	2.5	
Water		37.85

\* Aluminium zirconium tetrachlorohydro glycinate

A perfume composition embodying this invention was made and tested for deodorant action in an underarm product, using an Odour Reduction Value test generally as described  
 5 in US-A-4278658 using the formulation described in Formulation 3B. The perfume composition and the method for an Odour Reduction Value test are set out below.

Composition % by weight.	
5	ACETYL DI ISO AMYLENE
0.3	ADOXAL
8	BENZYL ACETATE EXTRA
10	BENZYL SALICYLATE
1.5	CASSIS BASE 345 AB 2967
1.5	CITRAL LEMAROME N

12	CITRONELLOL PURE
3	CYCLAMEN ALDEHYDE
0.3	EMPETAL
0.2	DUPICAL
1.5	AQUANAL
4.2	IONONE
8	LYRAL
1	METHYL OCTYL ACETALDEHYDE 10% DPG AA 191
5	MUGUET NATURE AB 1951
10	PHENYL ETHYL ALCOHOL
2	ROSACETONE
4	HABANOLIDE
7.5	TETRAHYDRO LINALOL
15	METHYL DIHYDRO JASMONATE

The Odour Reduction Value test was carried out using a panel of 40 Caucasian male subjects. A standard quantity (approximately 0.25g) of a roll-on product containing one of the perfume compositions or an unperfumed control was applied to the axillae of the panel members in accordance with a statistical design.

- 5 After a period of five hours the axillary odour was judged by three trained female assessors who scored the odour intensity on the 0 to 5 scale, as shown below

Score	Odour level	Conc. of aqueous isovaleric acid (ml/l)
0	No odour	0
1	Slight	0.013
2	Definite	0.053
3	Moderate	0.22
4	Strong	0.87
5	Very Strong	3.57

Average scores for each test product and the control product were then determined and the score for each test product was subtracted from the score for the control product to give the Odour Reduction Value.

- 10 The perfume composition described above contained 60.2% of active perfume components and was particularly effective in the Odour Reduction Value test.

**CLAIMS**

1. A cosmetic method for reducing or preventing body malodour by topically applying to human skin a composition comprising an active agent capable of inhibiting the production of odoriferous steroids by micro-organisms on the skin surface, wherein the agent is a perfume component which is capable of inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.
2. A method according to claim 1 wherein the composition is a perfume composition comprising at least 30% by weight of one or more of the perfume components capable of inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.
3. A method according to either one of claims 1 and 2 wherein the perfume component comprises at least one of the following materials  
(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl-cyclohex-2-en-1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methoxy)-4-propyl-1-benzenol), 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methyl-propanal,  $\alpha$ -ionone,  $\beta$ -ionone, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)-cyclohex-3-ene carbaldehyde, methyl iso-eugenol, tetrahydrolinalol, coriander, benzyl salicylate, dupical, phenyl ethyl alcohol, 9-decenol, clove leaf oil distilled, citral, vanillin.
4. A method according to any one of the preceding claims wherein an Odour Reduction Value of at least 10% is obtained.
5. A method according to any one of the preceding claims wherein the perfume component inhibits bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.
6. The use of a perfume component to inhibit bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.
7. The use of a perfume composition, comprising at least 30% by weight of one or more perfume components capable of inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase, to reduce body malodour.
8. The use of a deodorant product, comprising a perfume component, to reduce body malodour by inhibiting bacterial 4-ene reductase and/or 5 $\alpha$ -reductase.
9. A perfume composition comprising at least 30% by weight of one or more of the perfume components listed in claim 3.
10. A deodorant product comprising a perfume composition defined in claim 9.
11. A method of producing a perfume composition which comprises (i) evaluating perfume components on the ability to inhibit bacterial 4-ene reductase and/or 5 $\alpha$ -reductase, (ii) selecting perfume components on the ability to inhibit bacterial 4-ene reductase and/or 5 $\alpha$ -reductase, and (iii) mixing together two or more of said selected perfume components, optionally with other perfume components.
12. A method according to claim 11 wherein the selected perfume components are one or more of the perfume components listed in claim 3.

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 99/02170

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/32 A61K7/46

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 30689 A (PROCTER & GAMBLE) 28 August 1997 (1997-08-28) abstract example J examples 75-83 claims 1,3,4	1-3,9,10
X	EP 0 692 195 A (RHONE POULENC CHIMIE) 17 January 1996 (1996-01-17) page 2, line 46 - page 3, line 4 page 4, line 44 - line 56 claims 1,2,10,19	1-3,9,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 November 1999

Date of mailing of the international search report

10/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

## INTERNATIONAL SEARCH REPORT

Inter-Application No

PCT/GB 99/02170

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 260 053 A (CHAPPELL KATHERINE C ET AL) 9 November 1993 (1993-11-09) abstract column 1, line 9 - line 30 column 1; line 49 - line 68 column 2, line 62 -column 3, line 7 claims 1,2,15 ----	1,3
X	WO 98 16194 A (BEHAN JOHN MARTIN; MINHAS TONY (GB); HOOPER DAVID CHARLES (GB); PR) 23 April 1998 (1998-04-23) abstract page 1, paragraph 7 -page 4, paragraph 8 claims ----	1,3
X	US 5 554 588 A (BEHAN JOHN M ET AL) 10 September 1996 (1996-09-10) abstract examples 5-8 ----	1,3,4
A	FELLAHI Y ET AL: "Synthesis and antibacterial activity of 2-substituted 5-91,2 -diarylethyl)-4,6-dichloropyrimidine derivatives" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA, vol. 30, no. 7, 1 January 1995 (1995-01-01), page 633-639 XP004040189 ISSN: 0223-5234 abstract table IV page 636, column 1 -column 2 ----	1,8,10
A	FR 2 756 740 A (NISHIYAMA KENICHI) 12 June 1998 (1998-06-12) abstract page 1, line 5 - line 30 page 2, line 3 -page 3, line 2 page 4, line 6 - line 12 examples 3-5 page 11, line 22 - line 30 ----	1,8,10
A	MORRIS J A ET AL: "ANTIMICROBIAL ACTIVITY OF AROMA CHEMICALS AND ESSENTIAL OILS" JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, 1 May 1979 (1979-05-01), pages 595-603, XP000645444 ISSN: 0003-021X page 595, paragraph 1 - paragraph 3 table III -----	3

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/02170

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9730689 A	28-08-1997	CA 2246293 A EP 0886516 A	28-08-1997 30-12-1998
EP 0692195 A	17-01-1996	FR 2721922 A AU 697174 B AU 2324895 A BR 9502932 A CA 2152870 A CN 1118663 A CZ 9501704 A HU 72000 A JP 8012613 A NO 952575 A PL 309181 A US 5895657 A	05-01-1996 01-10-1998 11-01-1996 27-02-1996 30-12-1995 20-03-1996 17-01-1996 28-03-1996 16-01-1996 02-01-1996 08-01-1996 20-04-1999
US 5260053 A	09-11-1993	US 5256405 A CA 2086361 A GB 2262887 A,B JP 5337172 A	26-10-1993 01-07-1993 07-07-1993 21-12-1993
WO 9816194 A	23-04-1998	AU 4629697 A EP 0938288 A	11-05-1998 01-09-1999
US 5554588 A	10-09-1996	CA 2082281 A,C DE 69221087 D DE 69221087 T EP 0545556 A ES 2104850 T JP 5255689 A MX 9206423 A ZA 9208578 A	09-05-1993 04-09-1997 13-11-1997 09-06-1993 16-10-1997 05-10-1993 01-05-1993 06-05-1994
FR 2756740 A	12-06-1998	WO 9825624 A AU 1041597 A GB 2334445 A IT T0971062 A	18-06-1998 03-07-1998 25-08-1999 10-06-1998